⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGND News
Ligand Pharmaceuticals Inc.
Form 8-K
sec.gov
LGNDZ
LGND
LGNXZ
LGNYZ
LGNZZ
XOMA
Form 8-K
sec.gov
XOMAO
XOMAP
XOMA
LGND
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
globenewswire.com
LGND
XOMA
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
globenewswire.com
LGND
XOMA
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
LGND
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
globenewswire.com
TVTX
LGND
Form 8-K
sec.gov
SKYE
LGND
Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.
businesswire.com
LGND
Manufacturing Leaders Converged in Nashville for The Manufacturing & Automation eXchange (MAX)
accessnewswire.com
LGND
Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes
globenewswire.com
PFE
LLY
MGNX
LGND